Literature DB >> 9831387

A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasma.

C R Rodriguez1, D T Fei, B Keyt, D L Baly.   

Abstract

A specific and sensitive fluorometric enzyme-linked immunosorbent assay (ELISA) was developed to measure endogenous levels of vascular endothelial growth factor (VEGF165) in human plasma. The ELISA can be performed in 10% human EDTA plasma, yielding a neat plasma sensitivity of 10 pg/ml or 0.2 pM. The recovery of recombinant human VEGF (rhVEGF) added to human plasma ranges from 89 to 100%. The capture antibody depletes the endogenous signal in normal human plasma, suggesting that the signal is specific for VEGF. The inter-assay and intra-assay coefficients of variation (CV) for the ELISA ranges from 5 to 14% and 8 to 18%, respectively. Characterization of the ELISA using plasmin derived VEGF variants suggests the assay is specific for the VEGF165 isoform. The heterodimer, VEGF(165/110) quantitates similar to that of the intact VEGF165 homodimer, however, the homodimers VEGF121, VEGF110 and the carboxy terminal domain (residues 111-165) are not detected in the assay. Circulating endogenous VEGF levels measured in 50 normal healthy individuals range from 20 to 141 pg/ml, with a mean of 42 +/- 22 pg/ml. There were no significant differences in VEGF levels between males and females. Circulating endogenous VEGF levels in cancer patients ranged from 32 to 418 pg/ml, averaging 129 +/- 17 pg/ml.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831387     DOI: 10.1016/s0022-1759(98)00131-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  5 in total

Review 1.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Gene expression profiles of bronchoalveolar cells in pulmonary TB.

Authors:  Bindu Raju; Yoshihiko Hoshino; Ilana Belitskaya-Lévy; Rod Dawson; Stanley Ress; Jeffrey A Gold; Rany Condos; Richard Pine; Stuart Brown; Anna Nolan; William N Rom; Michael D Weiden
Journal:  Tuberculosis (Edinb)       Date:  2007-10-24       Impact factor: 3.131

3.  A phase II study of thalidomide in advanced metastatic renal cell carcinoma.

Authors:  David R Minor; Dana Monroe; Lisa A Damico; Gloria Meng; Uma Suryadevara; Laurence Elias
Journal:  Invest New Drugs       Date:  2002-11       Impact factor: 3.850

4.  Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours.

Authors:  S L Sheng; S H Bao; G Huang; L M Wang
Journal:  Clin Exp Immunol       Date:  2008-03       Impact factor: 4.330

5.  pHUSH: a single vector system for conditional gene expression.

Authors:  Daniel C Gray; Klaus P Hoeflich; Li Peng; Zhenyu Gu; Alvin Gogineni; Lesley J Murray; Mike Eby; Noelyn Kljavin; Somasekar Seshagiri; Mary J Cole; David P Davis
Journal:  BMC Biotechnol       Date:  2007-09-26       Impact factor: 2.563

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.